IL271256A - Compositions and methods for treating tauopathies - Google Patents

Compositions and methods for treating tauopathies

Info

Publication number
IL271256A
IL271256A IL271256A IL27125619A IL271256A IL 271256 A IL271256 A IL 271256A IL 271256 A IL271256 A IL 271256A IL 27125619 A IL27125619 A IL 27125619A IL 271256 A IL271256 A IL 271256A
Authority
IL
Israel
Prior art keywords
compositions
methods
treating tauopathies
tauopathies
treating
Prior art date
Application number
IL271256A
Other languages
Hebrew (he)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL271256A publication Critical patent/IL271256A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271256A 2017-06-16 2019-12-08 Compositions and methods for treating tauopathies IL271256A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/037991 WO2018231254A1 (en) 2017-06-16 2017-06-16 Compositions and methods for treating tauopathies

Publications (1)

Publication Number Publication Date
IL271256A true IL271256A (en) 2020-01-30

Family

ID=59388133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271256A IL271256A (en) 2017-06-16 2019-12-08 Compositions and methods for treating tauopathies

Country Status (11)

Country Link
EP (1) EP3638694A1 (en)
JP (2) JP2020529394A (en)
KR (1) KR20200018502A (en)
CN (1) CN110770253A (en)
AU (1) AU2017418317A1 (en)
BR (1) BR112019026298A2 (en)
CA (1) CA3064550A1 (en)
EA (1) EA202090063A1 (en)
IL (1) IL271256A (en)
MX (1) MX2019015071A (en)
WO (1) WO2018231254A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
DK3452507T3 (en) 2016-05-02 2022-11-14 Prothena Biosciences Ltd TAU IMMUNOTHERAPY
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
JP2020508054A (en) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. Anti-tau antibody and method of using the same
BR112019022906A2 (en) 2017-05-02 2020-05-26 Prothena Biosciences Limited ANTIBODIES THAT RECOGNIZE TAU
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CA3227440A1 (en) 2021-07-27 2023-02-02 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same
KR20230172262A (en) 2022-06-15 2023-12-22 재단법인대구경북과학기술원 Composition for preventing or treating tauopathy comprising PTK2 inhibitor as an active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
TR201802935T4 (en) * 2008-09-19 2018-03-21 Pfizer Stable liquid antibody formulation.
US8940272B2 (en) * 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
JP5941770B2 (en) 2012-06-28 2016-06-29 株式会社ミマキエンジニアリング Ink jet recording apparatus, liquid supply apparatus, and recording head cleaning method
SI2885010T1 (en) * 2012-08-16 2020-07-31 Ipierian, Inc. Methods of treating a tauopathy
EA039554B1 (en) * 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Method of reducing levels of a40 and/or a42 in a neuronal cell and/or in an extracellular fluid
WO2015081085A2 (en) * 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
BR112017007393A2 (en) * 2014-10-18 2017-12-19 Pfizer anti-il-7r antibody compositions

Also Published As

Publication number Publication date
CN110770253A (en) 2020-02-07
CA3064550A1 (en) 2018-12-20
EA202090063A1 (en) 2020-04-03
WO2018231254A1 (en) 2018-12-20
AU2017418317A1 (en) 2019-12-05
MX2019015071A (en) 2020-02-13
JP2020529394A (en) 2020-10-08
KR20200018502A (en) 2020-02-19
BR112019026298A2 (en) 2020-07-14
EP3638694A1 (en) 2020-04-22
JP2022033757A (en) 2022-03-02

Similar Documents

Publication Publication Date Title
IL267247B (en) Compositions and methods for treating cancer
IL266053A (en) Compositions and methods for treating ezh2-mediated cancer
IL269620A (en) Compositions and methods for treating phenylketonuria
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
IL274837A (en) Methods and compositions for treating cancers
IL271256A (en) Compositions and methods for treating tauopathies
IL269637A (en) Compositions and methods for treating synucleinopathies
ZA201805490B (en) Methods and compositions for treating hyperhidrosis
IL263460A (en) Compositions and methods for treating cardiovascular disease
LT3189074T (en) Compositions and methods for treating and preventing inflammation
PT4215527T (en) Compositions and methods for treating retinal degradation
DK3658142T3 (en) Compositions and methods for treating galactosemia
IL274524A (en) Compositions and methods for aquaculturing
PL3402575T4 (en) Methods and compositions for treating damaged hair
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL291266A (en) Compositions and methods for treating infections
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL269743A (en) Methods and compositions for treating retina-associated disease using ccr3-inhibitors
ZA201605109B (en) Compositions and methods for treating neutropenia
IL271923A (en) Methods and compositions for treating addictions
IL272782A (en) Compositions and methods for treating cancer
GB202001422D0 (en) Compositions and methods for preventing or treating nephrolithiasis
IL272945A (en) Topical compositions and methods for treatment
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
ZA201802268B (en) Methods and compositions for preventing or treating cancer